Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine

• Status: Unknown status
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label, single-center study to determine whether certain nasal medication interact with PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers and in patients with allergic rhinitis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Javelin Pharmaceuticals
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• Healthy adults

• Patients with Allergic Rhinitis

Exclusion Criteria:

• Under age 18